Form 4: Gilead Sciences Acquires Additional Stake in Assembly Biosciences Through Private Placement

Gilead Sciences increases its holdings in Assembly Biosciences via a private placement, acquiring common stock and warrants.

Summary

• Gilead Sciences, Inc. has increased its stake in Assembly Biosciences, Inc. through a private placement.
• On June 17, 2024, Gilead acquired 179,500 shares of Assembly Biosciences' common stock and a warrant to purchase an additional 179,500 shares.
• The combined purchase price was $15.46 per share of common stock and accompanying warrant.
• Following the transaction, Gilead Sciences beneficially owns 1,268,972 shares of Assembly Biosciences' common stock.
• The warrant is exercisable immediately and expires on June 18, 2029.
• The warrant cannot be exercised if it would result in Gilead Sciences and its affiliates owning more than 19.99% of Assembly Biosciences' outstanding common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a strategic investment by a major player (Gilead) in a smaller company (Assembly Biosciences), suggesting potential for future growth and collaboration. However, the ownership cap on the warrant exercise introduces a slight limitation.

Positives

• Gilead Sciences' increased investment in Assembly Biosciences could signal confidence in the latter's prospects.
• The private placement provides Assembly Biosciences with additional capital.
• The warrant provides Gilead with the potential to further increase its stake in Assembly Biosciences in the future.

Risks

• The warrant includes an ownership cap of 19.99%, limiting Gilead's potential future stake in Assembly Biosciences.
• The value of the warrant is dependent on the future performance of Assembly Biosciences' common stock.

Future Outlook

Gilead Sciences may exercise its warrant to purchase additional shares of Assembly Biosciences common stock in the future, subject to the ownership cap.

Industry Context

This investment reflects ongoing activity in the biotechnology sector, where larger companies often invest in or acquire smaller firms with promising technologies or drug candidates.

Related Party Transactions

• The purchase of shares and warrants by Gilead Sciences from Assembly Biosciences constitutes a related party transaction.

Stakeholder Impact

• Shareholders of Assembly Biosciences may view this investment positively, as it could lead to increased stock value.
• Employees of Assembly Biosciences may benefit from the increased financial stability and potential for growth.
• Gilead Sciences' shareholders may see this as a strategic move to expand their portfolio.

Next Steps

• Gilead Sciences may choose to exercise its warrant to purchase additional shares of Assembly Biosciences common stock before the expiration date.
• Assembly Biosciences will likely use the capital raised from the private placement for its operational needs.

Key Dates